SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma()()

Hepatocellular carcinoma is the fifth most common solid cancer worldwide. Sorafenib, a small multikinase inhibitor, is the only approved therapy for advanced HCC. The clinical benefit of sorafenib is offset by the acquisition of sorafenib resistance. Understanding of the molecular mechanism of STAT3...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Su, Jung-Chen, Tseng, Ping-Hui, Wu, Szu-Hsien, Hsu, Cheng-Yi, Tai, Wei-Tien, Li, Yong-Shi, Chen, I-Ting, Liu, Chun-Yu, Chen, Kuen-Feng, Shiau, Chung-Wai
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Neoplasia Press 2014
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4198826/
https://ncbi.nlm.nih.gov/pubmed/25047655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2014.06.005
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन